Related Experiment Video

Updated: Feb 14, 2026

In Silico Clinical Trials for Cardiovascular Disease
09:09

In Silico Clinical Trials for Cardiovascular Disease

Published on: May 27, 2022

2.3K

Malignant mesothelioma clinical trial combines immunotherapy drugs

Monica S Chatwal1, Tawee Tanvetyanon2

  • 1Division of Medicine, Division of Hematology/Oncology, University of South Florida/H Lee Moffitt Cancer Center, Tampa, FL 33612, USA.

Immunotherapy
|February 24, 2018
PubMed

Insights

Combining PD-1/PD-L1 inhibitors with CTLA-4 inhibitors in malignant mesothelioma shows feasibility and modestly higher response rates. However, this approach also increases severe immunotherapy-related toxicities, necessitating further investigation.

Area of Science:

  • Oncology
  • Immunology

Background:

  • Malignant mesothelioma treatment remains challenging, with limited efficacy of single-agent PD-1 or PD-L1 inhibitors showing response rates of 10-20%.
  • Rationale for combining PD-1/PD-L1 inhibitors with CTLA-4 inhibitors in mesothelioma is based on successful outcomes in melanoma.

Discussion:

  • Recent clinical trials investigated the combination of PD-1/PD-L1 inhibitors and CTLA-4 inhibitors in mesothelioma.
  • These studies, despite small sample sizes, demonstrated the feasibility of this combined immunotherapy approach.
  • A modestly higher tumor response rate was observed compared to single-agent therapies.

Key Insights:

  • The combination therapy suggests improved efficacy in malignant mesothelioma.
  • Increased toxicity, including immunotherapy-related deaths (encephalitis, renal failure, hepatitis), is a significant concern.

Outlook:

  • Further clinical studies are warranted to optimize the combination immunotherapy regimen.
  • Balancing efficacy and toxicity is crucial for future treatment strategies in malignant mesothelioma.
Keywords:
immune checkpoint inhibitorimmunotherapyipilimumabmesotheliomanivolumab

More Related Videos

Generation and Expansion of Primary, Malignant Pleural Mesothelioma Tumor Lines08:01

Generation and Expansion of Primary, Malignant Pleural Mesothelioma Tumor Lines

Published on: April 21, 2022

2.3K
Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation15:04

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Published on: January 19, 2019

12.8K

Related Concept Videos

Clinical Trials01:16

Clinical Trials

Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
10.9K
Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
5.0K
Statistical Software for Data Analysis and Clinical Trials01:12

Statistical Software for Data Analysis and Clinical Trials

Statistical software is pivotal in data analysis and clinical trials by providing tools to analyze data, draw conclusions, and make predictions. These software packages range from simple data management applications to complex analytical platforms, supporting various statistical tests, models, and simulation techniques. Their significance lies in their ability to handle vast amounts of data with precision and efficiency, enabling researchers to validate hypotheses, identify trends, and make...
1.6K
Combined Effects of Drugs: Synergism01:27

Combined Effects of Drugs: Synergism

Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
7.0K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.0K
Combined Effects of Drugs: Antagonism01:30

Combined Effects of Drugs: Antagonism

The combined effects of drugs can result in various interactions, of which an important type is antagonism. Antagonism is a mechanism where one drug inhibits or counteracts the effects of another drug. Antagonism can occur through various means, including receptor binding, allosteric modulation, functional interaction, chemical reactions, and pharmacokinetic processes.
The most common type is receptor antagonism, where one drug acts as an antagonist to block the effects of another drug by...
11.8K